BIOV.SW Bioversys AG

Healthcare Biotechnology SIX Swiss Exchange
23.50 CHF
Close of Oct 30, 2026
21.20 30.70
Market cap
CHF 138M
P/E
-
P/B
3.06x
ROE
-36.5%
Dividend yield
-
Fundamental score
1.3/5

Ratios use the latest price and the fiscal year ending Dec 2025.

Is BIOV.SW undervalued?

Graham number

The Graham number of Bioversys AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bioversys AG fundamental analysis

6 of 21 checks passed

ROE 0/2

Low return on equity (-48.7%), below 10%.

ROA 1/1

Return on assets (-28.4%) is above the industry median (-45.6%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (-17.9%) is above the industry median (-30.9%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (48.5%), up to 100%.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Cash Runway 2/2

Cash covers 3.1 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (3.1x) is above the industry median (3.1x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Bioversys AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bioversys AG

BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a researc…

Full company profile